NCT06597734View on ClinicalTrials.gov

A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm

PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

January 28, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2029

Conditions
Chronic Myelomonocytic LeukemiaAdvanced Myeloproliferative NeoplasmsIDH1-mutated Higher-Risk Myelodysplastic Syndromes
Interventions
DRUG

Olutasidenib

Given by PO

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Rigel Pharmaceuticals
All Listed Sponsors
collaborator

Rigel Pharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER